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POTENTIAL RELEVANCE OF BELL-SHAPED AND U-SHAPED DOSE-RESPONSES
FOR THE THERAPEUTIC TARGETING OF ANGIOGENESIS IN CANCER
Andrew R. Reynolds   Tumor Angiogenesis Group, The Breakthrough Breast
Cancer Research Centre, The Institute of Cancer Research, London, U.K.
 Tumor angiogenesis, the growth of new blood vessels into tumors, facilitates tumor
growth and thus represents an attractive therapeutic target. Numerous experimental
angiogenesis inhibitors have been characterised and subsequently trialled in patients.
Some of these agents have failed to show any substantial activity in patients. In contrast,
others have been more successful, but even these provide only a few months extra patient
survival. Recent work has focused on understanding the effects of anti-angiogenic agents
on tumor biology and has revealed a number of new findings that may help to explain the
limited efficacy of angiogenesis inhibitors. Herein, I review the evidence that hormetic
dose-responses (i.e. bell-shaped and U-shaped dose-response curves) are often observed
with anti-angiogenic agents. Agents reported to exhibit these types of dose-response
include: 5-fluorouracil, ATN-161, bortezomib, cisplatin, endostatin, enterostatin, integrin
inhibitors, interferon-α, plasminogen activator-1 (PAI-1), rapamycin, rosiglitazone, statins,
thrombospondin-1, TGF-α1 and TGF-α3. Hormesis may also be relevant for drugs that tar-
get the vascular endothelial growth factor (VEGF) signalling pathway and for metronom-
ic chemotherapy. Here I argue that hormetic dose-responses present a challenge for the
clinical translation of several anti-angiogenic agents and discuss how these problems might
be circumvented.
Keywords: angiogenesis, anti-angiogenic therapy, hormesis, biphasic, chemotherapy, 
pharmacodynamics
1. INTRODUCTION TO ANTI-ANGIOGENIC THERAPY
1.1 The concept of tumor angiogenesis and anti-angiogenic therapy
The growth of tumors is dependent on an adequate supply of oxygen
and nutrients, which are supplied to the tumor by blood vessels. Extensive
evidence shows that tumor progression is dependent on tumor angio-
genesis i.e. the growth of new blood vessels into tumors. It was the late
Judah Folkman who first pioneered the idea that: (a) tumor angiogene-
sis drives aggressive tumor growth, and (b) inhibition of tumor angio-
genesis should be an effective way to block tumor growth (Folkman
1971). In support of this idea, a great deal of pre-clinical work has shown
that angiogenesis inhibitors can suppress tumor growth and this has driv-
en the clinical translation of angiogenesis inhibitors (Kerbel and
Folkman 2002; Folkman 2007).
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Folkman also proposed that anti-angiogenic therapy should have a
number of advantages over conventional chemotherapy. Firstly, since
angiogenesis occurs in most tumor types, anti-angiogenic therapy should
be an effective treatment strategy for most cancers. Secondly, since angio-
genesis inhibitors target the genetically stable tumor vasculature, therapy
resistance should be minimal. Thirdly, since the adult vasculature is most-
ly quiescent (angiogenesis is a rare process in the healthy adult body)
toxic side-effects of anti-angiogenic therapies should be minimal.
Although this logic appeared to be apparently sound, evidence is accu-
mulating to suggest that (a) anti-angiogenic therapy may only be effective
against certain types of cancer, (b) anti-angiogenic drugs can have toxic
side effects, and (c) acquired resistance to angiogenesis inhibitors can
occur (Kamba and McDonald 2007; Bergers and Hanahan 2008; Hutson
et al. 2008; Shojaei and Ferrara 2008; Blowers and Hall 2009; Ebos et al.
2009b; Eikesdal and Kalluri 2009).
1.2 Molecular players in the angiogenic switch 
Tumor angiogenesis is considered to be regulated by an “angiogenic
switch” that relies on a change in the local concentrations of pro-angio-
genic and anti-angiogenic mediators in the tumor microenvironment in
favour of tumor angiogenesis (Hanahan and Folkman 1996). Vascular
endothelial growth factor (VEGF), a pro-angiogenic growth factor
expressed by virtually all solid cancers, is considered to be the principal
growth factor via which tumors induce angiogenesis. VEGF is released
from tumor cells and tumor stromal cells and binds to two cognate VEGF
receptors, VEGF receptor 1 (VEGFR1) and VEGF receptor 2 (VEGFR2),
which are expressed on local vascular endothelial cells (Olsson et al.
2006). Signalling through these receptors drives the process of angio-
genesis, which involves dissolution of the vascular basement membrane,
endothelial cell proliferation, endothelial cell migration and formation
of new blood vessels that grow into the tumor (Carmeliet 2000). The
VEGF signalling system appears to be a highly ‘druggable’ target and
potent inhibitors of the VEGF signalling pathway have been developed
(Ferrara et al. 2004; Ferrara and Kerbel 2005; Ellis and Hicklin 2008;
Kerbel 2008). 
The process of angiogenesis involves the coordinated regulation of
many aspects of cell behaviour. For example, in order for endothelial
cells to migrate and form new blood vessels, changes in the actin
cytoskeleton and alterations in cell adhesion must occur. The involve-
ment of these processes in angiogenesis has spurred the development of
other types of angiogenesis inhibitors, including inhibitors of cell adhe-
sion (Hood and Cheresh 2002; Tucker 2003). Moreover, numerous
endogenous proteins that exhibit angiogenesis inhibitory activity have
A. R. Reynolds
254
2
Dose-Response: An International Journal, Vol. 8 [2014], Iss. 3, Art. 3
https://scholarworks.umass.edu/dose_response/vol8/iss3/3
been characterised, including endostatin and angiostatin. Coordinated
down-regulation of these molecules is believed to be necessary for initia-
tion of angiogenesis. These endogenous angiogenesis inhibitors have
therefore also been utilised as potential therapeutic agents (Clamp and
Jayson 2005; Folkman 2006). 
1.3. Clinical translation of anti-angiogenic therapy
Although numerous angiogenesis inhibitors have been characterised
only a handful of these agents have yielded promising results in patients.
For example, a number of agents reported to successfully suppress angio-
genesis and tumor growth in tumor-bearing mice have not shown equiva-
lent results in patients. These include integrin inhibitors (e.g. cilengitide)
and naturally occurring angiogenesis inhibitors (e.g. endostatin). As a
consequence, these agents have yet to be licensed for use in patients. 
The most successful anti-angiogenic agents trialled in patients thus
far are drugs that target the VEGF signalling pathway. At the time of writ-
ing, three agents in this class have been licensed for the treatment of can-
cer patients: bevacizumab, sunitinib and sorafenib. Bevacizumab is a
humanised monoclonal antibody that binds VEGF and prevents its
binding to cognate VEGF receptors, whilst sunitinib and sorafenib are
small molecule drugs that potently inhibit the tyrosine kinase activity of
several receptors, including VEGFR1, VEGFR2, PDGFR and KIT recep-
tor (Folkman 2007; Ellis and Hicklin 2008). Sunitinib monotherapy has
been reported to extend progression free survival and overall survival
in patients with metastatic renal cancer (Motzer et al. 2007; Motzer et al.
2009), whilst bevacizumab can extend progression–free survival in sev-
eral cancers, including metastatic colorectal, lung and breast cancers
when used in combination with chemotherapy (Hurwitz et al. 2004;
Sandler et al. 2006; Miller et al. 2007). However, benefits in overall sur-
vival afforded by bevacizumab are reported as being insignificant in sev-
eral trials (Escudier et al. 2007; Miller et al. 2007; Saltz et al. 2008), whilst
other trials show that overall survival can, at best, only be extended by
a few months (Hurwitz et al. 2004; Sandler et al. 2006). In summary,
experience in the clinic with the VEGF pathway inhibitors shows that,
(a) whilst some patients respond to these agents, others do not, (b) cer-
tain cancers appear more sensitive to these agents than others, (c)
although some cancers can respond to these drugs when administered
as monotherapy (e.g. sunitinib in renal cancer), in most cases these
agents must be combined with other drugs to be effective (e.g. beva-
cizumab in colorectal cancer), and (d) although patients can respond
initially to therapy, the development of resistance is a problem. The
mechanisms which underlie these observations are poorly understood
(Ebos et al. 2009b).
Hormesis and anti-angiogenic therapy
255
3
Reynolds: Hormesis and anti-angiogenic therapy
Published by ScholarWorks@UMass Amherst, 2014
1.4 Resistance and host response to anti-angiogenic therapy 
Recent work from many groups has focused on understanding the
effects of angiogenesis inhibitors on tumor biology. This work has begun
to reveal why tumors can be refractory or acquire resistance to anti-angio-
genic agents. Some of these findings are briefly discussed below. 
As well as expressing VEGF, tumors can express other pro-angiogenic
growth factors, such as fibroblast growth factor 2 (FGF2) or placental
growth factor (Fujimoto et al. 1995; Relf et al. 1997; Smith et al. 1999; Parr
et al. 2005) that could theoretically substitute for VEGF and result in
angiogenesis even when VEGF-signalling is blocked. It has been suggest-
ed that the presence of these alternative factors in anti-angiogenic-thera-
py naïve tumors might cause tumors to be refractory to VEGF inhibition
or that up-regulation of these factors during the course of therapy could
lead to acquired resistance to VEGF pathway inhibition (Casanovas et al.
2005; Kerbel 2005; Bergers and Hanahan 2008). 
Apart from changes in growth factor expression, other aspects of the
tumor microenvironment may be important for resistance. For example,
resistance to VEGF-pathway inhibitors has been linked with tumor
recruitment of endothelial progenitor cells, myeloid cells or fibroblasts.
These cells may render tumors insensitive to anti-angiogenic therapy,
either by directly incorporating into the vasculature or by secreting fac-
tors that promote endothelial or tumor cell survival (Rafii et al. 2002;
Orimo et al. 2005; Bertolini et al. 2006; De Palma and Naldini 2006;
Murdoch et al. 2008; Shojaei and Ferrara 2008; Crawford et al. 2009).
Angiogenesis may not be the only mechanism via which tumors
acquire a vasculature. In particular, a number of tumors have been shown
to access a blood supply by hijacking existing local blood vessels (Pezzella
et al. 1997; Holash et al. 1999; Rubenstein et al. 2000; Leenders et al. 2004).
In this scenario, tumor cells grow along existing blood vessels, or remod-
el local existing blood vessels as they invade. The mechanisms that medi-
ate this ‘vascular co-option’ process are largely unknown, but it is likely
that this type of tumor vascularisation may be insensitive to conventional
anti-angiogenic agents or may provide an escape mechanism from anti-
angiogenic therapy. 
Arguably, the most surprising observations regarding the effects of
anti-angiogenic agents are the recently published data showing that,
whilst VEGF pathway inhibitors can suppress tumor growth, they may also
actually promote invasive tumor growth and distant tumor metastasis in
mice (Ebos et al. 2009a; Paez-Ribes et al. 2009). Clearly, if such effects are
also observed in humans, this could be a mechanism that could seriously
compromise the ability of anti-angiogenic therapy to extend patient sur-
vival and could explain the rapid progression of disease that is sometimes
observed after cessation of anti-angiogenic therapy in cancer patients
(Ebos et al. 2009b). 
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Anti-angiogenic agents also face another problem that has, thus far,
received little emphasis in the literature. Molecules with anti-angiogenic
activity often appear to exhibit hormesis i.e. bell-shaped or U-shaped
dose-response curves. The remainder of this review will discuss the evi-
dence for hormesis in angiogenesis and its possible relevance for anti-
angiogenic therapy in human cancer patients. 
2. HORMESIS AND ANGIOGENESIS
2.1 Dose-response models
The fundamental nature of the dose-response to drugs is generally
considered to be sigmoidal (Fig. 1a). At low concentrations, drugs are
assumed to have no significant biological effect, until a threshold is met
whereby inhibition proceeds in a linear fashion until saturation is
achieved. This concept of the dose-response, known as the threshold
model, has dominated the field of pharmacology and medicine for most
of the 20th century (Calabrese 2009). During this period of time, cancer
patients have been routinely treated with chemotherapy drugs at the
maximum tolerated dose. According to the threshold dose-response
model, this should maximise the chance of eradicating all tumor cells and
yield the best therapeutic index (Korn et al. 2001; Fox et al. 2002). 
However, extensive evidence suggests that the threshold dose-
response model may be an inadequate model to explain the pharmaco-
dynamics of many anti-cancer compounds. Instead, the dose-response to
many drugs may be preferentially modelled using ‘hormetic’ or ‘bipha-
sic’ dose-response models (Calabrese and Baldwin 2003; Calabrese et al.
2006b; Calabrese et al. 2008). Hormesis can manifest in several forms:
bell-shaped, U-shaped or J-shaped dose-response curves. A bell-shaped
dose-response is characterized by low-dose stimulation, followed by loss of
this effect at higher doses (Fig. 1b). An agent displaying a bell-shaped
dose-response may often show inhibitory activity at higher doses (Fig.
1b). In a U-shaped dose-response, low concentrations of drug have an
inhibitory effect that is lost at higher concentrations (Fig 1c). Sometimes,
an agent displaying a U-shaped dose-response may even have a stimula-
tory effect at higher doses, which is referred to as a J-shaped dose-
response (Fig. 1c) (Calabrese 2005; Calabrese et al. 2006a). 
2.2 Bell-shaped and U-shaped dose-responses in angiogenesis
The literature contains several reports of molecules that can stimulate
angiogenesis at low concentrations, whilst inhibiting angiogenesis at
higher doses, i.e. a bell-shaped dose-response. These molecules include:
bortezomib (Veschini et al. 2007), HMG-CoA reductase inhibitors
(Urbich et al. 2002; Weis et al. 2002), plasminogen activator-1 (PAI-1)
(Devy et al. 2002), RGD-mimetic integrin inhibitors (Reynolds et al. 2009;
Hormesis and anti-angiogenic therapy
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Weis et al. 2009), TGF-β1 (Pepper et al. 1993; Lebrin et al. 2005) and TGF-
β3 (Goumans et al. 2002). Several reports of molecules that only inhibit
angiogenesis at low doses can also be found, i.e. a U-shaped dose-
response curve. These include endostatin (Celik et al. 2005; Tjin Tham
Sjin et al. 2006), integrin inhibitor ATN-161 (Donate et al. 2008), inter-
feron-α (Slaton et al. 1999) the mTOR inhibitor rapamycin (Humar et al.
2002; Bruns et al. 2004), the PPARγ ligand rosiglitazone (Panigrahy et al.
2002) and the satiety peptide enterostatin (Park et al. 2008). Finally,
thrombospondin-1 has been reported to exhibit both a bell-shaped dose-
A. R. Reynolds
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FIGURE 1. Generic appearance of the threshold, bell-shaped and U/J-shaped dose response curves.
(a) A threshold dose-response, where low concentrations of an agent exert no effect until a thresh-
old is reached. At this threshold concentration, inhibition occurs linearly in a dose-dependent fash-
ion, until saturation is achieved. (b) A bell-shaped dose-response, where an agent exerts a stimulato-
ry effect at low doses, which is diminished at higher doses. At higher doses, an inhibitory effect may
be observed. (c) A U-shaped or J-shaped dose-response, where inhibition is observed only when the
agent is present at low concentrations. At higher concentrations, this inhibitory effect is lost and a
stimulatory effect may even be observed.
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response (Motegi et al. 2002; Motegi et al. 2008) and a U-shaped dose-
response (Tolsma et al. 1993; Miao et al. 2001).
Unfortunately, there is insufficient space here to discuss the implica-
tions of all these papers, so here I will focus specifically on RGD-mimetic
integrin inhibitors and thrombospondin-1 as examples of compounds
that can give rise to a bell-shaped dose-response, whilst endostatin, ATN-
161 and thrombospondin-1 will be used as examples of agents that display
U-shaped dose-responses. Finally, I will review the evidence that hormesis
has relevance for VEGF pathway inhibitors and for a form of anti-angio-
genic therapy known as metronomic chemotherapy. 
3. RGD-MIMETIC INTEGRIN INHIBITORS
3.1 Anti-angiogenic therapy via targeting of αvβ3- and αvβ5-integrin
Integrins are cell adhesion molecules that regulate diverse cellular
functions during the process of angiogenesis and tumor progression,
including cell migration, cell proliferation and cell survival (Hood and
Cheresh 2002; Hynes et al. 2002). The integrins αvβ3 and αvβ5 can be
expressed both by tumor cells and tumor endothelial cells (Varner and
Cheresh 1996). Drugs that inhibit integrin function may be able to block
tumor growth in at least two ways: by targeting the function of integrins
in tumor cells directly and by inhibiting tumor angiogenesis (Brooks et al.
1994a; Brooks et al. 1994b; Brooks et al. 1995; Varner and Cheresh 1996;
Hodivala-Dilke et al. 2003; Tucker 2003). The αvβ3 and αvβ5 integrins
mediate cell adhesion by binding to an arginine-glycine-aspartate (RGD)
sequence that is present in various extracellular matrix molecules
(Ruoslahti and Pierschbacher 1987). Ligand competitive inhibitors, or
‘RGD-mimetic integrin inhibitors,’ have been designed to block this
interaction. Existing αvβ3/αvβ5–integrin inhibitors include the
RGD–mimetic cyclic peptide, cilengitide (EMD 121974) (Dechantsreiter
et al. 1999; Nisato et al. 2003) and RGD–mimetic small molecules such as
S 36578 (Perron-Sierra et al. 2002; Maubant et al. 2006). Cilengitide is cur-
rently in phase 1 and 2 clinical trials for cancer therapy. Initial trials of
cilengitide in human cancer demonstrated that the drug was well-tolerat-
ed, but that it offered little significant clinical benefit in the majority of
patients (Eskens et al. 2003; Friess et al. 2006; Hariharan et al. 2007).
However, some glioma patients respond to cilengitide when it is adminis-
tered at high doses (Nabors et al. 2007) or when it is combined with radi-
ation therapy and temozolimide (Stupp 2007). 
3.2 Pre-clinical evidence for a bell-shaped dose-response to RGD-mimetic
integrin inhibitors 
Within a few hours after administration of an integrin inhibitor bolus
to mice, plasma concentrations of inhibitor fall rapidly from micromolar
Hormesis and anti-angiogenic therapy
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to nanomolar levels (Reynolds et al. 2009). We therefore investigated
whether nanomolar doses of integrin inhibitors could have different
effects on tumor growth and angiogenesis as compared to micromolar
doses of integrin inhibitors. Surprisingly, we found that low (nanomolar)
concentrations of RGD–mimetic αvβ3/αvβ5–inhibitors could actually
stimulate angiogenesis within in vitro models and stimulate tumor growth
and angiogenesis in subcutaneous tumor grafts in mice. We found clear
evidence that the dose-response to these agents is bell-shaped, with low
(nanomolar) concentrations of αvβ3/αvβ5–inhibitors stimulating angio-
genesis, whilst high (micromolar) concentrations of αvβ3/αvβ5–
inhibitors inhibited angiogenesis (Reynolds et al. 2009).
Although these observations were at first surprising to us, we found
previously published work suggesting that low concentrations of RGD
peptides might be able to activate integrins or promote cell migration
(Aznavoorian et al. 1990; Legler et al. 2001; Hynes 2002; Weis et al. 2009).
Endothelial cell migration is an essential component of angiogenesis.
Moreover, the intracellular recycling of various cell surface molecules,
such as integrins and growth factor receptors, is a vital process during cell
migration (Bretscher 1996; Jones et al. 2006; Caswell and Norman 2008).
We showed that nanomolar concentrations of αvβ3/αvβ5–integrin
inhibitors promoted the recycling of both αvβ3–integrin and VEGFR2.
Importantly, when we inhibited this recycling, the ability of αvβ3/
αvβ5–inhibitors to promote angiogenesis was ablated (Reynolds et al.
2009). In concordance with our observations, a second study showed that
cilengitide can promote tumor cell invasion within in vitro models
(Caswell et al. 2008). Combined, these data suggest that integrin
inhibitors may sometimes be able to promote tumor progression.
3.3 Relevance of the bell-shaped dose-response for the clinical translation
of integrin inhibitors
How do these findings assist in our understanding of how to apply
RGD-mimetic integrin inhibitors in the clinic? The data suggest that
whilst high concentrations of integrin inhibitors may provide a therapeu-
tic effect, low concentrations may be detrimental and promote angio-
genesis and tumor growth. At the time of writing, there is debate as to
whether low concentrations of cilengitide will have the same effect in
human tumors (Reynolds and Hodivala-Dilke 2009; Weis et al. 2009;
Weller et al. 2009).
Importantly, in current trials of cilengitide, the drug is being admin-
istered at high doses or in combination with other therapies (Weller et al.
2009). Conceivably, this type of administration may circumvent the dele-
terious side effects that we and others have reported with cilengitide. Of
interest, we found that the tumor growth promoting effect of integrin
inhibitors was ablated if mice were co-administered a VEGFR2 function-
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blocking antibody (Reynolds et al. 2009). This suggests that it may be rea-
sonable to test the combination of VEGF inhibitors with integrin
inhibitors in clinical trials. In support of this, Strieth and co-workers
demonstrated that the combination of anti-integrin and anti-VEGF ther-
apy was highly effective in suppressing tumor growth in A-Mel-3
melanoma tumors grown subcutaneously in Syrian golden hamsters
(Strieth et al. 2006). Interestingly, a trial combining VEGF-inhibition with
integrin inhibition is being planned for glioma patients (Elizabeth
Gerstner, personal communication). In this trial, VEGF pathway inhibi-
tion will be achieved using cediranib, a small molecule tyrosine kinase
inhibitor that inhibits VEGFR2 (Wedge et al. 2005), and the integrin
inhibitor to be used is cilengitide. It is hoped that this combination will
show activity in cancer patients.
4. ENDOSTATIN
4.1 Pre-clinical evidence for a U-shaped dose-response to endostatin
Endostatin is an endogenously expressed 20 kDa proteolytic fragment
derived from the C-terminus of type XVIII collagen. Endostatin can
inhibit endothelial cell proliferation and migration in vitro and treatment
of mice with endostatin can inhibit tumor growth in mice by suppression
of tumor angiogenesis (Boehm et al. 1997; O’Reilly et al. 1997; Folkman
2006). Phase 1 and 2 studies of endostatin in patients showed that treat-
ment with endostatin is associated with minimal toxicity but, thus far,
impressive therapeutic effects have not been reported (Eder et al. 2002;
Kulke et al. 2006). Trials of endostatin in the USA were terminated at the
phase 2 stage. Here I discuss the evidence for a U-shaped dose-response
to endostatin and its relevance for the clinical translation of endostatin as
an anti-cancer agent.
Two reports demonstrated that endostatin exhibits a U-shaped dose-
response curve with respect to inhibition of tumor growth (Celik et al.
2005; Tjin Tham Sjin et al. 2006). Both papers showed that the growth of
human pancreatic cancer cell lines in mice is inhibited by low doses of
endostatin, but that the therapeutic efficacy of endostatin is lost once the
dose is increased. Celik found that, in BxPC-3 tumor-bearing mice, the
maximally effective dose was 100 mg/kg/day endostatin, where circulat-
ing endostatin levels were 9.14 ± 4.67 ng/ml. For AsPC-1 tumor-bearing
mice, the maximally effective dose was slightly higher at 500 mg/kg/day
(circulating endostatin levels were 62.2 ± 22.9 ng/ml). For both tumor
types, an increase in dosage to 1000 mg/kg/day resulted in elevated cir-
culating endostatin levels in excess of 100 ng/ml and was correlated with
reduced therapeutic efficacy of endostatin. In addition Tjin Tham Sijn et
al., found that, for BxPC-3 tumor-bearing mice, the optimal circulating
concentration of endostatin to achieve anti-tumor effects was between
Hormesis and anti-angiogenic therapy
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126-175 ng/ml, but that therapeutic efficacy was lost at higher endostatin
dosages, where circulating concentrations were increased to 580 ng/ml
(Tjin Tham Sjin et al. 2006). These data suggest that endostatin displays
maximal anti-tumor effects only when circulating concentrations are
within a low dose range.
4.2 Clinical relevance of the U-shaped dose-response to endostatin
The observation of a U-shaped dose-response curve for the anti-
tumor efficacy of endostatin may explain some clinical observations with
this agent. Davis and co-workers examined angiogenesis markers, i.e.
tumor microvessel density and endothelial cell apoptosis, in tumor biop-
sies obtained from patients before and after endostatin therapy in a phase
1 trial (Davis et al. 2004). Although this was a retrospective study which
only incorporated data from 17 patients, the authors were able to con-
clude that the anti-angiogenic activity of endostatin was more pro-
nounced in patients treated with an endostatin dose of around 250
mg/m2, whereas anti-angiogenic activity tended to be less apparent in
patients treated with lower or higher doses of endostatin (Davis et al.
2004). Moreover, a study that used PET scanning to measure tumor blood
flow also showed that there may be a U-shaped relationship between
endostatin dose and inhibition of angiogenesis in patients (Herbst et al.
2002). These studies suggest that the anti-angiogenic activity of endo-
statin in humans may indeed be U-shaped.
Another curious clinical observation that might be explained by the
U-shaped dose-response to endostatin comes from numerous studies that
have correlated elevated levels of endostatin with a poorer prognosis. For
example, renal cancer patients who showed an increase in circulating lev-
els of endostatin after nephrectomy had a significantly poorer prognosis
than patients without such an increase (Feldman et al. 2002). In fact,
when Clamp and Jayson reviewed 14 studies that examined the relation-
ship between circulating endostatin and prognosis, they found that whilst
5/14 studies demonstrated no relationship, a staggering 8/14 studies cor-
related raised serum endostatin with a poorer prognosis, whilst only one
study correlated raised serum endostatin levels with a better prognosis
(Clamp and Jayson 2005). Given that endostatin is anti-angiogenic, it is
puzzling to see that elevated endostatin levels are associated with a poor-
er prognosis. However, one possible explanation is that the anti-angio-
genic and anti-tumor effect of endostatin is U- or J-shaped. Under those
circumstances, elevated serum endostatin levels would not be beneficial
and only serum endostatin levels within an appropriate low dose thera-
peutic window would confer a better prognosis. Collectively, these find-
ings provide clinical evidence that the anti-angiogenic activity of endo-
statin in patients is U-shaped.
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Importantly, a phase 1 trial of endostatin was designed without prior
knowledge of this U-shaped dose-response curve and adopted the usual
method of dose-escalation in order to determine toxicity and efficacy
(Eder et al. 2002). In a subsequent phase 2 trial, endostatin was typically
dosed at levels that resulted in circulating concentrations of endostatin
exceeding 100 ng/ml (Kulke et al. 2006). Importantly, significant anti-
tumor effects were rarely observed in these trials. Based on the data I
have discussed herein, it is intriguing to speculate that the lack of effica-
cy observed with endostatin may have occurred because patients received
a dose of endostatin that was, in many cases, too high to be beneficial.
4.3 Clinical challenges associated with the U-shaped dose-response to
endostatin
How could these observations guide future attempts to use endostatin
as an anti-angiogenic agent? The U-shaped dose-response to endostatin
suggests that the efficacy of endostatin therapy is likely dependant on
baseline circulating endostatin levels. Circulating levels of endogenous
endostatin in healthy subjects vary between individuals and lie in the
range 10-50 ng/ml in serum and 40-100 ng/ml in plasma. Moreover, cir-
culating levels of endostatin in cancer patients can increase above base-
line levels by two-fold or more (Feldman et al. 2000; Feldman et al. 2002;
Ohlund et al. 2008). It would therefore be extremely important to meas-
ure base-line circulating endostatin levels before and during therapy to
establish the optimal dose of endostatin to be administered. A patient
with low, sub-therapeutic levels of circulating endostatin might benefit
from endostatin therapy if this shifts their circulating levels into the ther-
apeutically active low dose range (Fig. 2a). However, a patient with high-
er circulating levels of endostatin may not benefit from endostatin thera-
py if this shifts their circulating endostatin concentration to a higher
level, that is beyond the therapeutically active low-dose range (Fig. 2b).
Moreover, if the patient demonstrates circulating endostatin levels that
far exceed the therapeutic range, the U-shaped dose- response curve sug-
gests that it may in fact be more desirable to suppress circulating levels of
endostatin in these patients rather than augment it by administration of
endostatin (Fig. 2c).
The existence of a U-shaped curve also suggests that continuous infu-
sion of endostatin at a constant dose might be more effective than admin-
istration of the drug as a bolus. Interestingly, it has been shown that con-
tinuous delivery of endostatin to mice using osmotic minipumps is more
effective in inhibiting pancreatic tumor growth than daily bolus injec-
tions (Kisker et al. 2001; Capillo et al. 2003). Although the reasoning for
this is unknown, an attractive explanation for this finding is that whilst
bolus administration of endostatin results in exposure of the tumor to a
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broad range of endostatin concentrations, continuous infusion may
maintain circulating endostatin levels within a low dose range that is ther-
apeutically active. 
5. THE INTEGRIN INHIBITOR ATN-161 
5.1 Pre-clinical evidence for the U-shaped dose-response to ATN-161
ATN-161 is an integrin inhibitor based on an amino acid sequence
(PHSRN) found within the ‘synergy region’ of the integrin ligand
A. R. Reynolds
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FIGURE 2. Clinical relevance of the U-shaped dose-response to endostatin. This figure illustrates the
potential relevance of the U-shaped dose-response for anti-angiogenic therapy with endostatin. (a) A
patient with baseline low levels of circulating endostatin (black dot) might benefit from endostatin
therapy if this shifts the circulating endostatin levels into the therapeutically active low dose window
(white dot). (b) A patient with baseline mid-range circulating levels of endostatin (black dot) might
not benefit from endostatin therapy if the administration of endostatin shifts the circulating plasma
concentration to a higher level (white dot) that is beyond the therapeutic window. (c) A patient with
very high baseline circulating endostatin levels (black dot) might actually benefit from measures
designed to reduce circulating levels of endostatin (white dot). 
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fibronectin. However, in the ATN-161 peptide, the naturally occurring
arginine is replaced with a cysteine i.e. PHSCN. The compound shows
anti-tumor and anti-angiogenic activity in vivo (Livant et al. 2000;
Stoeltzing et al. 2003; Khalili et al. 2006). In a more recent study, the anti-
angiogenic activity of ATN-161 in vivo was shown to be U-shaped with max-
imal anti-angiogenic activity observed when mice were administered the
drug at 1 or 5 mg/kg/day, with loss of activity at ≥ 10 mg/kg/day doses
and beyond (Donate et al. 2008). There is no published mechanistic data
to explain why a U-shaped dose-response curve is observed with ATN-161.
The finding that the integrin inhibitor ATN-161 exhibits a U-shaped
dose-response curve is particularly interesting, since this would appear to
contradict findings that RGD-mimetic integrin inhibitors, such as cilengi-
tide, exhibit the opposite shape of curve i.e. a bell-shaped dose-response
curve (Reynolds et al. 2009). However, it is important to note that ATN-
161 and cilengitide differ, both in terms of the types of integrin they bind
to and the mechanism via which they inhibit the integrins. Firstly, whilst
cilengitide is a relatively selective inhibitor of αvβ3-integrin and αvβ5-
integrin (Dechantsreiter et al. 1999; Perron-Sierra et al. 2002), ATN-161
interacts instead with αvβ3-integrin and α5β1-integrin (Donate et al.
2008). Secondly, cilengitide inhibits cell adhesion by competing for bind-
ing of the integrin to the RGD-sequence contained in many natural inte-
grin ligands, including fibronectin and vitronectin. In contrast, the ATN-
161 peptide is not an RGD-competitive compound and is proposed to
inhibit integrin activation by forming a disulphide bridge with a key cys-
teine residue involved in conformational activation of the integrin
(Donate et al. 2008). The existence of these differences may account, at
least in part, for the radically different dose-response curves observed
with cilengitide and ATN-161.
5.2 Clinical relevance of the ATN-161 U-shaped dose-response
Testing of ATN-161 in a phase 1 trial showed that this compound has
anti-tumor activity in patients (Cianfrocca et al. 2006). As Donate and col-
leagues point out, the presence of a U-shaped dose-response curve presents
a significant challenge for effective dosing with ATN-161 in phase 2 trials
that are ongoing (Donate et al. 2008). However, the timely discovery of the
U-shaped dose-response curve means that this can be accounted for in the
design of phase 2 trials, an advantage that was not afforded to endostatin. 
6. THROMBOSPONDIN-1
6.1. Evidence that thrombospondin-1 exhibits bell-shaped and U-shaped
dose-responses
The thrombospondins are a family of high molecular weight (420-520
kDa) extracellular matrix glycoproteins (Zhang and Lawler 2007). The
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anti-angiogenic activity of thrombospondin-1 (TSP-1) may occur via sev-
eral mechanisms, including inhibition of endothelial cell migration,
induction of endothelial cell apoptosis and altered regulation of growth
factors, cytokines, nitric oxide and proteases that regulate the process of
angiogenesis (Zhang and Lawler 2007). However, TSP-1 has also been
associated with pro-angiogenic effects (Taraboletti et al. 2000). Two
recent papers illustrate that the response of endothelial cells to TSP-1 is
bell-shaped. Whilst TSP-1 concentrations of ≥ 50 g/ml and above inhibit-
ed endothelial cell migration, concentrations in the range 0.1-10 g/ml
TSP-1 resulted in enhanced endothelial cell migration (Motegi et al. 2002;
Motegi et al. 2008). Importantly, the expression of TSP-1 in human
tumors is very heterogeneous, with concentrations ranging from 17.4 to
23,400 g of TSP-1 per gram of cytosol protein reported in human breast
carcinoma (Pratt et al. 1989). As Motegi and colleagues point out (Motegi
et al. 2008), pathological examination of human tumors has lead to con-
flicting reports relating TSP-1 expression to tumor angiogenesis and
patient prognosis. Whilst some reports demonstrate that TSP-1 expres-
sion is correlated with angiogenesis inhibition and a better prognosis
(Yao et al. 2000; Mehta et al. 2001; Kishi et al. 2003; Macluskey et al. 2006)
other studies report that TSP-1 expression is correlated with increased
angiogenesis and a poorer prognosis (Kasper et al. 2001; Straume and
Akslen 2001). The finding that TSP-1 exhibits a bell-shaped curve with
respect to angiogenesis inhibition provides a possible explanation for
these apparently conflicting findings (Motegi et al. 2008).
In contrast, other studies have shown that the angiogenic response to
TSP-1 is U-shaped. Tolsma and colleagues showed that although TSP-1
can inhibit FGF2-stimulated angiogenesis in vivo, the response to TSP-1 in
vitro within an FGF2-stimulated endothelial cell migration assay was
markedly U-shaped (Tolsma et al. 1993). Likewise, another study showed
that whilst TSP-1 could inhibit tumor growth in vivo, FGF2-stimulated
endothelial cell migration was U-shaped with respect to TSP-1 concentra-
tion (Miao et al. 2001). However, this may be a property that is unique to
the intact TSP-1 molecule and might not be displayed by sub-fragments
of TSP-1, because a peptide corresponding to a 50/70 kDa central por-
tion of TSP-1 inhibited endothelial migration to FGF2 without showing a
U-shaped dose-response (Tolsma et al. 1993). This 50/70 kDa peptide cor-
responded to a region containing the TSP-1 type 1 and TSP-1 type 2
repeats of the molecule. 
6.2 Clinical relevance for anti-angiogenic therapy with thrombospondin-1
The bell-shaped and U-shaped dose-responses to TSP-1 may have con-
sequences for anti-angiogenic therapy. Recombinant TSP-1 and peptide
fragments of TSP-1 have been shown to inhibit tumor growth and angio-
genesis in pre-clinical models. The active peptide fragments are based on
A. R. Reynolds
266
14
Dose-Response: An International Journal, Vol. 8 [2014], Iss. 3, Art. 3
https://scholarworks.umass.edu/dose_response/vol8/iss3/3
sequences contained in the TSP-1 type 1 repeat region located in the mid-
dle portion of TSP-1 and include the peptides denoted 3TSR and ABT-
510 (Zhang and Lawler 2007). In particular, ABT-510 is being tested in
clinical trials, but to date has shown little activity when administered as a
single agent in phase 2 trials (Ebbinghaus et al. 2007; Zhang and Lawler
2007; Baker et al. 2008). Given that both bell-shaped and U-shaped dose-
responses have been observed with TSP-1, it will be important to test the
angiogenic response to these peptides at a broad range of concentrations
to elucidate whether these peptides can also elicit similar effects. 
Interestingly, it has been shown that continuous delivery of 3TSR to
mice using osmotic minipumps is more effective in inhibiting tumor
growth than daily bolus injections (Zhang et al. 2007). Although the rea-
soning for this is unknown, a possible explanation for this finding is that
whilst bolus administration of 3TSR results in exposure of the tumor to
both angiogenesis promoting and inhibiting concentrations, continuous
infusion may maintain plasma 3TSR levels at a concentration that is
exclusively in the angiogenesis-inhibitory zone. 
7. THE POTENTIAL RELEVANCE OF BELL-SHAPED AND U-SHAPED
RESPONSES FOR VEGF-MEDIATED VASCULARIZATION AND
 THERAPEUTIC INHIBITION OF THE VEGF PATHWAY
VEGF plays a key role in both developmental vascularization and
tumor angiogenesis. Moreover, as already mentioned, the most successful
anti-angiogenic agents applied thus far in the clinic are the VEGF path-
way inhibitors, such as the VEGF-neutralising antibody, bevacizumab, or
the VEGF receptor tyrosine kinase inhibitor, sunitinib. To the best of this
author’s knowledge, there is currently little published evidence to show
that VEGF pathway inhibitors exhibit a bell-shaped, U-shaped or J-shaped
dose-response. However, here I will discuss some anecdotal observations
that may point to the relevance of hormesis for the process of VEGF-
mediated vascularization and agents that target the VEGF pathway.
7.1 Developmental angiogenesis
Studies in mice in which VEGF has been genetically deleted or over-
expressed suggest that, during embryonic development, the dose of
VEGF required for development of a normal vasculature may be bell-
shaped. Deletion of both alleles of the VEGF gene results in embryonic
lethality due to severe vascular defects (Ferrara et al. 1996) illustrating the
essential function of VEGF for the development of the embryonic vascu-
lature. Moreover, surprisingly, deletion of just one VEGF allele in mice
also results in embryonic lethality due to vascular defects (Carmeliet et al.
1996). This is highly unusual, as deletion of one allele rarely gives rise to
such a severe phenotype. Moreover, over-expression of VEGF in mice at a
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level that is 2-3 fold that of normal levels also results in embryonic lethal-
ity due to vascular defects (Miquerol et al. 2000). Combined, these data
suggest that VEGF levels need to be tightly controlled for normal vascu-
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FIGURE 3. Hormetic dose-response relationships for VEGF-induced vascularization and VEGF path-
way inhibition. (a) Studies examining the relationship between the expression level of VEGF and the
development of a functional vasculature in mice suggest the existence of a bell-shaped dose-response
curve. Low expression of VEGF is insufficient to induce the formation of a functional vasculature,
whilst over-expression of VEGF induces the formation of a dysfunctional vasculature. (b) The con-
cept of vascular normalization may be depicted in the form of a bell-shaped dose-response curve.
Low doses of inhibitor may be insufficient to normalise the vasculature, whilst higher doses of
inhibitor may lead to excessive destruction of the vasculature and loss of vascular normalization. (c)
A trade-off between maximising therapeutic effects and minimising adverse effects can be depicted
with a U-shaped curve. Inhibition of tumor growth is assumed to correlate with increasing drug dose
exposure (blue line). However, adverse effects are also assumed to correlate with increasing dose
exposure (red line). According to this model, the optimal dose is found at the base of the U-shaped
curve (marked by the black circle). In contrast, lower or higher doses (marked by white circles) are
less optimal. 
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lar patterning during embryonic development. Too little VEGF or too
much VEGF results in failure to form a functional vasculature. In a sense
then, VEGF expression during development exhibits a bell-shaped curve
with respect to successful formation of a functional vasculature (Fig 3a). 
7.2. Vascular normalization
The tumor vasculature is chaotic and dysfunctional (Jain 2001; Jain
2005). This may be a direct consequence of excessive production of
VEGF in the tumor microenvironment, as suggested by the bell-shaped
dose-response to VEGF observed in studies of the effect of VEGF dosage
on vascular development (see Section 7.1). Based on this assumption, it
might be assumed that administering a low dose of VEGF pathway
inhibitor could potentially improve tumor vascularization and actually
promote tumor growth. However, no evidence for such a phenomenon
has so far been presented.
In fact, improvements in tumor vascularization have been suggested
as a desirable consequence of VEGF pathway inhibition. Rakesh Jain and
co-workers have demonstrated that VEGF inhibition can, at least tran-
siently, improve the quality of the tumor vasculature (so-called ‘vascular
normalization’) that in turn may lead to improved drug penetration into
tumors (Jain 2001; Jain 2005). This may explain why the combination of
bevacizumab with chemotherapy can be more beneficial than chemother-
apy alone (Hurwitz et al. 2004; Sandler et al. 2006; Miller et al. 2007).
However, Jain has also pointed out that continued repetitive administra-
tion of anti-angiogenic therapy may result in over-destruction of the vas-
culature, with resulting reduced vascular function, which would actually
impede the efficacy of co-administered therapy (Jain 2005). Theoretically
therefore, to achieve successful vascular normalization, a low dose of
VEGF pathway inhibitor might be more effective than a higher dose. In a
sense then, the inhibition of VEGF signalling with respect to vascular nor-
malization may exhibit a bell-shaped relationship (Fig 3b). 
7.3 A U-shaped curve could be relevant for the optimal dosing of VEGF
pathway inhibitors 
Administration of VEGF-signalling inhibitors has been linked to sev-
eral undesirable side effects. Therapy-associated toxicities observed in
patients include hypertension, fatigue, proteinuria, thromboembolic
events, bleeding, cardiac toxicity, lymphopenia, neutropenia, wound-
healing complications and gastrointestinal perforations (Hutson et al.
2008; Blowers and Hall 2009). Moreover, recent data obtained in mice
suggest that inhibitors of the VEGF pathway may induce damage to the
vessels of normal organs (Kamba and McDonald 2007) and promote
increased tumor invasion and increased tumor metastasis (Ebos et al.
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2009a; Ebos et al. 2009b; Paez-Ribes et al. 2009). In general, the efficacy of
VEGF-targeted therapy is considered to increase with the dose adminis-
tered, therefore VEGF pathway inhibitors are generally administered at
the maximum tolerated dose. However, if the above listed adverse side
effects are assumed to increase in severity with increasing dose of drug,
then it may be preferable to administer lower doses. Therefore, the most
suitable dose of VEGF-targeted agent may be a trade-off between using a
dose that is sufficient to achieve anti-tumor efficacy, without inducing
undesirable side effects. Therefore, a U-shaped curve might be relevant
to the optimal dosing of VEGF-targeted therapy (Fig 3c). 
Is there evidence to suggest that lower doses of VEGF-targeted agents
are more successful in the clinic than higher doses? One phase 2 study of
bevacuzimab observed that response rates, progression free survival and
overall survival were all more favourable in metastatic colorectal cancer
patients treated with a lower dose of bevacizumab than patients treated
with a higher dose (Kabbinavar et al. 2003). If a lower dose of bevacizum-
ab is more effective than a higher dose, then this might suggest the exis-
tence of a U-shaped dose-response curve. However, a subsequently pub-
lished phase 2 study in patients with non small cell lung cancer showed
that a greater benefit was observed in patients treated with a higher dose
of bevacizumab compared to a lower dose of bevacizumab (Johnson et al.
2004). A recently published meta-analysis that examined the relationship
between drug exposure and outcomes in patients treated with sunitinib
found that increased exposure to sunitinib is associated with improved
clinical outcomes, but also some increased risk of adverse effects (Houk
et al. 2009). Importantly, the standard dose of sunitinib is 50 mg per day,
but dose reductions were required in approximately 30% of renal cancer
patients treated with sunitinib in order to manage the significant toxici-
ties of this agent (Motzer et al. 2007). On balance then, the available clin-
ical data suggest that although the maximal therapeutic benefit of VEGF-
targeted therapy is probably correlated with a higher dose exposure, it
may sometimes be advantageous to use lower doses in some patients.
7.4 Consequences for potential stimulation of tumor growth by low doses
of VEGF pathway inhibitors
As alluded to earlier, it has been reported that several molecules dis-
playing anti-angiogenic activity at high doses may actually be able to stim-
ulate angiogenesis at lower doses (see Section 2.2). There is currently no
published data demonstrating that low doses of VEGF pathway inhibitors
can stimulate angiogenesis or tumor growth. However, if subsequent work
shows that low doses of VEGF pathway inhibitors can promote tumor
growth, what would be the consequences for therapy with these agents?
Tyrosine kinase inhibitors (TKIs) designed to inhibit VEGF receptor sig-
nalling (e.g. sunitinib) are often administered in a discontinuous fashion
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to patients. For example, sunitinib is commonly administered in a 6 week
cycle, where the patient takes the drug every day for 4 weeks, followed by
a 2 week drug-free period (Motzer et al. 2007; Burstein et al. 2008). It has
been reported that rapid resumption of tumor growth can occur in
patients during the 2 week drug-free period in the clinic (Burstein et al.
2008). It is likely that this break in therapy is also accompanied by a grad-
ual drop in circulating concentrations of sunitinib. If these low concen-
trations can promote tumor growth, then this could potentially stimulate
tumor re-growth during the break period. Importantly, it is known that
rapid vascular regrowth can occur in mouse tumor models upon with-
drawal of a TKI (Mancuso et al. 2006). It is possible that this vascular re-
growth is just a consequence of removing the inhibitor. However, if low
doses of TKIs can indeed promote tumor angiogenesis, then this could
fuel rapid resumption of tumor growth during the break period.
Therefore, the effect of low TKI doses on angiogenesis needs to be
addressed. In the case that low doses of TKIs can promote angiogenesis,
then the dosing regimen for such TKIs may need to be reviewed.
8. EVIDENCE FOR HORMESIS IN METRONOMIC CHEMOTHERAPY
Conventional therapeutic strategies for cancer have been dominated
by the use of cytotoxic agents, which are typically DNA damaging agents
(e.g. cisplatin), anti-metabolites (e.g. 5-fluorouracil) or microtubule dis-
rupting agents (e.g. paclitaxel) that are designed to kill rapidly dividing
cancer cells. These drugs are also toxic to other cell types and can lead to
unpleasant side effects, such as myelosuppression, fatigue and nausea,
and must be administered at a dose that avoids life-threatening toxicity.
For this reason, they are typically administered once per week for several
weeks at the maximum tolerated dose, followed by a break of several days
or weeks, before resumption of therapy. 
In a landmark study, Browder and colleagues showed that daily low
dose administration of the chemotherapy agent cyclophosphamide
results in inhibition of tumor growth due to anti-angiogenic effects
(Browder et al. 2000). Similar studies showed that other chemotherapeu-
tic agents, including vinblastine and paclitaxel, can also inhibit tumor
growth due to anti-angiogenic effects when administered frequently at
low doses (Klement et al. 2000; Klement et al. 2002). This approach,
known as metronomic chemotherapy, has shown promising results in
clinical trials (Kerbel and Kamen 2004; Emmenegger and Kerbel 2007).
The approach also has the advantage that toxicities associated with high-
er doses of chemotherapy are avoided. 
Interestingly, two papers from Albertsson and co-workers suggest that
some chemotherapy agents might actually promote angiogenesis at low
doses. These authors found that although continuous low dose adminis-
tration of cyclophosphamide or paclitaxel was anti-angiogenic, continu-
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ous low-dose administration of 5-fluorouracil or cisplatin could some-
times promote VEGF-A mediated angiogenesis, an effect that was not
observed when 5-fluorouracil or cisplatin compounds were administered
at higher doses (Albertsson et al. 2008; Albertsson et al. 2009). The angio-
genic response to 5-fluorouracil or cisplatin may therefore be bell-
shaped. It is important to note that these experiments were performed
using a rat mesentery assay of angiogenesis and effects on tumor growth
and tumor angiogenesis were not examined. However, these findings do
suggest that not all chemotherapy drugs may be suitable for metronomic
chemotherapy in patients.
9. FUTURE DIRECTIONS
I have reviewed some of the data demonstrating that hormesis is rel-
evant for angiogenesis and anti-angiogenic therapy. It is clear that whilst
hormesis appears frequently in the angiogenesis literature, it is a poorly
understood phenomenon that creates certain challenges for effective
anti-angiogenic therapy. In the following section, I will summarise how
the problem of hormesis might be approached in the future. 
9.1 Selection of anti-angiogenic agents at the research and development
stage
There is great interest in the development of novel, anti-angiogenic
agents (Folkman 2007). The knowledge that anti-angiogenic agents can
display hormetic properties has implications for the selection of suitable
anti-angiogenic agents at the research and development stage, prior to
entry into the clinic. Potential novel anti-angiogenic agents should there-
fore be screened in suitable assays at a wide range of doses to examine for
the existence of hormetic properties. Agents that display dramatic
hormetic properties could then be excluded from clinical development,
in preference for agents that display little or no hormesis. Alarmingly, a
recent study that examined the dose-response to a library of anticancer
agents in a high throughput assay format demonstrated that more potent
compounds (i.e. compounds with a lower IC50) were also more likely to
exhibit stimulatory effects on cell growth when present at lower concen-
trations (Nascarella and Calabrese 2009). Since compounds are often
selected on the basis that they have a low IC50, this highlights the need
to screen compounds for activity at a broader range of concentrations.
9.2 Implications for VEGF-targeted therapies
In this article I have postulated that hormesis may be relevant to the
biology of VEGF and VEGF pathway inhibitors. However, at the time of
writing, no single study has convincingly demonstrated hormetic respons-
es to VEGF pathway inhibitors. In contrast, hormesis has been demon-
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strated convincingly for a number of angiogenesis inhibitors that have yet
to be approved for therapeutic use in humans. Given the pitfalls associat-
ed with using agents that exhibit hormesis as therapeutic agents, it is
tempting to speculate that the success of VEGF pathway inhibitors can be
attributed, at least in part, to a lack of hormesis. That said, the survival
benefit afforded by VEGF pathway inhibitors is still only measured in
terms of months (Ebos et al. 2009b). I have discussed here how U-shaped
and bell-shaped biology may be relevant for VEGF pathway inhibitors, but
this is mostly speculation. Future studies may reveal whether hormesis is
relevant for therapeutic inhibition of VEGF signalling and whether it is
necessary to account for these effects in order to achieve a greater thera-
peutic index with these agents.
9.3 Dosing of anti-angiogenic agents
Anti-angiogenic agents are generally administered to patients as a
bolus dose, either orally or intravenously. Importantly, repeated adminis-
tration of a bolus results in fluctuating circulating concentrations of the
agent due to drug metabolism (Fig 4a). For an agent that exhibits a
hormetic dose-response, bolus dosing may not be an optimal method of
drug administration. In the case of agents with a bell-shaped dose-
response curve, although administration of a bolus dose can result tran-
siently in a therapeutically active high concentration of drug shortly after
administration, there will also be a period of time where the circulating
levels of drug fall to a concentration range which is pro-angiogenic (Fig
4b). In the case of agents with a U-shaped or J-shaped dose-response
curve, the drug concentration may be ineffective or even pro-angiogenic
shortly after administration, with drug concentrations that have an anti-
angiogenic activity only being achieved at later time points (Fig 4c). This
suggests that, in order to be most effective, such agents should be deliv-
ered in a way that either (a) maintains the circulating level of drug at a
high concentration (in the case of agents with a bell-shaped dose
response, Fig 4b) or (b) maintains the level of drug at a low concentration
(in the case of agents with a U-shaped or J-shaped dose-response, Fig 4c).
Interestingly, studies performed in pre-clinical models may provide
support for this idea. There are numerous studies conducted in mice
which show that maintaining a constant circulating dose of angiogenesis
inhibitor (via continuous infusion of the agent) is more effective than
administering the agent as a bolus, which results in fluctuating circulat-
ing concentrations (Morishita et al. 1995; Drixler et al. 2000; Kisker et al.
2001; Capillo et al. 2003; Kumar et al. 2007; Zhang et al. 2007).
Importantly, several of the agents used in these studies, including endo-
statin (Kisker et al. 2001) and TSP-1 (Zhang et al. 2007), have been shown
to exhibit bell- or U-shaped dose-response curves. This presents a possi-
ble explanation for the increased efficacy achieved when a constant cir-
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culating concentration is maintained i.e. it avoids exposure of the subject
to low and high doses which may have potentially deleterious side-effects.
There may, of course, be other explanations as to why administration of
a constant dose level is more effective. Firstly, blood vessels may be fun-
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FIGURE 4. Consequences of hormesis for administration of drugs as a bolus. (a) Repeated adminis-
tration of a drug as a bolus results in fluctuating circulating concentrations of drug. (b) For an agent
that exhibits a bell-shaped dose-response, this results transiently in a therapeutically active high con-
centration of drug shortly after administration (black shading), followed later by a period of time
where the circulating levels of drug fall to a concentration range which may be detrimental, e.g. pro-
angiogenic (red shading). This suggests that, in order to be most effective, agents that exhibit a bell-
shaped response should ideally be delivered continuously at a high dose (grey dashed line). (c) For
an agent that exhibits a U-shaped or J-shaped dose-response curve, the drug concentration may be
ineffective or detrimental, e.g. pro-angiogenic, shortly after administration (red shading), with drug
concentrations that are therapeutically active only being achieved at later time points (black shad-
ing). This suggests that, in order to be most effective, agents that exhibit a U-shaped or J-shaped dose-
response should ideally be maintained at a constant level in the circulation (grey dashed line).
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damentally more sensitive to angiogenesis inhibitors when administered
at a constant dose, due to some aspect of vascular biology that is not com-
pletely understood. For example, tumor blood vessels have been report-
ed to rapidly re-grow upon withdrawal of anti-angiogenic therapy
(Mancuso et al. 2006). It may be that by maintaining a constant dose of
anti-angiogenic agent, such vascular re-growth is suppressed. Secondly,
since angiogenesis inhibitors can have a short half-life in vivo, adminis-
tration of the agent continuously might, in some cases, achieve a larger
area under the curve (AUC) than bolus dosing. Since there is evidence
for a positive correlation between AUC and anti-tumor efficacy for at least
one type of anti-angiogenic agent (Houk et al. 2009), this may be anoth-
er explanation for the greater efficacy observed when circulating con-
centrations are maintained at a constant dose level.
To the best of this author’s knowledge, no clinical trial has ever com-
pared administration of an anti-angiogenic agent as a bolus with adminis-
tration of the same agent as a continuous infusion. Given the predominant
observation that continuous dosing is more effective than bolus dosing in
pre-clinical models, these different methods of dosing anti-angiogenic
therapy should be compared in an appropriately designed clinical trial. 
9.4 Using biomarkers to determine the optimal dose
Traditionally, anti-cancer agents are administered at the maximum
tolerated dose in order to achieve maximum cancer cell kill. However,
agents that display a U-shaped dose-response curve, such as endostatin or
ATN-161, need to be administered at an optimal dose that is well below
the maximum tolerated dose. This is challenging, but might be assisted
by using a surrogate biomarker for anti-tumor efficacy. The existence of
circulating endothelial cells is well documented and it has been suggest-
ed that these cells may represent a surrogate marker for the efficacy of
anti-angiogenic therapy in humans (Bertolini et al. 2006; Strijbos et al.
2008). Encouragingly, Celik and colleagues demonstrated that a thera-
peutically active dose of endostatin in mice was correlated with a reduc-
tion in the numbers of circulating endothelial cells (Celik et al. 2005).
Likewise, a therapeutically active dose of ATN-161 in mice was also corre-
lated with a reduction in circulating endothelial cells (Donate et al. 2008).
Therefore, measurement of circulating endothelial cells in patients might
represent a suitable surrogate biomarker for effective dosing of agents
displaying a U-shaped curve. 
9.5 Combining anti-angiogenic agents with other therapeutic modalities
I have described how it is necessary to deliver the biologically active
dose in order to achieve a therapeutic response with an agent that
exhibits hormesis. However, the pitfalls associated with an agent that dis-
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plays hormesis might also be overcome by administering the agent in
combination with a second drug. In this case, the second drug would be
selected on the basis that it counteracts the hormetic effects of the
hormetic agent. In support of this, our recent work showed that the
hormetic effects of an integrin inhibitor could be ablated by combination
with a VEGF receptor inhibitor (Reynolds et al. 2009). Another study also
showed that the combination of an integrin inhibitor with a VEGF recep-
tor inhibitor gave rise to synergistic anti-tumor activity (Strieth et al.
2006). Importantly, the VEGF-inhibitor bevacizumab has shown efficacy
when used in combination with chemotherapy, demonstrating that anti-
angiogenic agents can be effectively combined with other agents in the
clinic. Research identifying the mechanisms of hormesis in angiogenesis
may give rise to other rational strategies to combine anti-angiogenic ther-
apies with other therapeutic modalities.
9.6 Molecular mechanisms of hormesis in angiogenesis
An area that has been largely unexplored is the understanding of how
hormesis influences blood vessel formation at the molecular level. Whilst
many studies report that anti-angiogenic agents have hormetic proper-
ties, few address the underlying biochemical mechanisms. Firstly, it is pos-
sible that binding of an anti-angiogenic agent to one receptor may medi-
ate different outcomes at different doses by acting solely through that
receptor. This may be especially true for integrins, which appear to play
both a negative and positive role in angiogenesis (Hodivala-Dilke et al.
2003). In support of this, we showed that integrin inhibitors can elicit
both pro- and anti-angiogenic effects by acting through the same integrin
(Reynolds et al. 2009). Secondly, an anti-angiogenic agent may bind to
two or more receptors, with one receptor mediating pro-angiogenic
effects and the other mediating anti-angiogenic effects. This may be the
case for certain growth factors, such as the TGF-β family of growth fac-
tors (Goumans et al. 2002). Thirdly, anti-angiogenic proteins, such as
endostatin or thrombospondin, may contain both pro-angiogenic and
anti-angiogenic sequences (Karagiannis and Popel 2007) and the balance
of activity mediated by these different sequences may mediate the phe-
nomenon of hormesis. These molecular mechanisms may have conse-
quences for the control of blood vessel formation and the application of
angiogenesis inhibitors in the clinic.
10. CONCLUSION
In conclusion, hormesis is relevant for angiogenesis and for thera-
peutic angiogenesis inhibition. The existence of hormesis presents a sig-
nificant challenge for anti-angiogenic therapy. Continuing research into
this phenomenon may lead to new insights, both for our understanding
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of the basic mechanisms of angiogenesis and for the application of anti-
angiogenic therapy in cancer patients. 
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